Monte Rosa Therapeutics Inc Asset Turnover Ratio (GLUE), as of first quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Monte Rosa Therapeutics Inc   (NASDAQ: GLUE)
 

Monte Rosa Therapeutics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Due to the increase in investments during the first quarter 2026, Monte Rosa Therapeutics Inc 's asset turnover ratio sequentially decreased to 0.09 in the first quarter (Mar 31 2026), this is lower than usual.

Within sector 49 more businesses have achieved higher asset turnover ratio. While ranking the asset turnover ratio, among all other companies, it is fair to say, that the company's position has deteriorated in the First Quarter 2026 compared to the preceding quarter from 2364 to 3140.

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLUE Asset Turnover Ratio (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Asset Change 89.01 % 3.16 % 46.45 % 4.21 % 48.67 %
Y / Y Revenue Change -95.04 % -95.41 % 38.54 % 394.01 % 7882.05 %
Asset Turnover Ratio (TTM) 0.09 0.3 0.44 0.48 0.43
GLUE's Total Ranking # 3140 # 2364 # 2068 # 1886 # 251
Seq. Asset Change 64.14 % -1.7 % 28.38 % -8.75 % -10.42 %
Seq. Revenue Change 51.38 % -78.22 % -44.95 % -72.69 % 40.04 %



Asset Turnover Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 50
Healthcare Sector # 478
Overall Market # 3140

Asset Turnover Ratio Statistics
High Average Low
0.47 0.32 0.09
(Jun 30 2025)   (Mar 31 2026)




GLUE Company Profile • Back to GLUE Efficiency Comparisons • Compare GLUE Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Mar 31 2026 Assets at quarter ending Mar 31 2026
Maxcyte inc   0.16 $ 32.287  Millions$ 207.552  Millions
Skinvisible Inc   0.15 $ 0.020  Millions$ 0.131  Millions
China Pharma Holdings Inc  0.15 $ 3.992  Millions$ 26.429  Millions
Autolus Therapeutics Plc  0.15 $ 92.624  Millions$ 624.765  Millions
Standard Biotools Inc   0.15 $ 85.215  Millions$ 575.867  Millions
Lineage Cell Therapeutics Inc   0.15 $ 14.779  Millions$ 100.639  Millions
Nektar Therapeutics  0.14 $ 55.633  Millions$ 388.140  Millions
Femasys Inc   0.14 $ 2.377  Millions$ 16.823  Millions
Safe Pro Group Inc   0.13 $ 1.642  Millions$ 12.272  Millions
Scilex Holding Company  0.13 $ 33.862  Millions$ 254.563  Millions
Foghorn Therapeutics Inc   0.13 $ 28.224  Millions$ 212.867  Millions
Septerna Inc   0.13 $ 72.255  Millions$ 546.940  Millions
Ispecimen inc   0.13 $ 1.027  Millions$ 7.793  Millions
Petvivo Holdings Inc   0.13 $ 0.821  Millions$ 6.266  Millions
Igc Pharma Inc   0.13 $ 1.166  Millions$ 8.905  Millions
Renovorx Inc   0.13 $ 1.489  Millions$ 11.727  Millions
Coherus Oncology inc   0.13 $ 46.883  Millions$ 370.087  Millions
Royalty Pharma Plc  0.13 $ 2,440.522  Millions$ 19,276.619  Millions
Bioadaptives Inc   0.13 $ 0.024  Millions$ 0.190  Millions
Ginkgo Bioworks Holdings Inc   0.12 $ 141.311  Millions$ 1,143.236  Millions
Lucid Diagnostics Inc   0.12 $ 5.134  Millions$ 41.598  Millions
Nurix Therapeutics Inc   0.12 $ 71.779  Millions$ 609.573  Millions
Seastar Medical Holding Corp  0.12 $ 1.436  Millions$ 12.334  Millions
Xencor Inc  0.12 $ 97.360  Millions$ 840.144  Millions
Beam Therapeutics Inc   0.12 $ 164.011  Millions$ 1,416.053  Millions
Arvinas Inc   0.11 $ 89.400  Millions$ 779.750  Millions
C4 Therapeutics Inc   0.11 $ 34.861  Millions$ 312.488  Millions
Sintx Technologies Inc   0.11 $ 1.029  Millions$ 9.469  Millions
Protagonist Therapeutics inc   0.11 $ 74.063  Millions$ 696.335  Millions
Bolt Biotherapeutics Inc   0.11 $ 6.499  Millions$ 61.332  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.